返回
摘要
En
Keyword:
REACTION-TIME
期刊
IF:
3.2
论文数:
2.5W
被引数:
1.9W
机构
暂无机构信息
引用论文
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer卡铂和紫杉醇联合或不联合血管破坏剂Vadimezan (ASA404) 治疗晚期非小细胞肺癌的随机III期安慰剂对照试验

